Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
3215-70-1
Molecular formula
C22H32N2O6
Molecular weight
420.5 g/mol
Drug class
Selective beta-2 adrenergic receptor agonistsympathomimetic bronchodilator and tocolytic
Mechanism of action
Stimulates beta-2 adrenergic receptors, increasing intracellular cyclic AMP and relaxing bronchial and uterine smooth muscle.
Indications / reported uses
Bronchodilation in reversible airway obstruction where authorised.
Tocolysis or suppression of premature uterine contractions in jurisdictions and formulations where authorised.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Hexoprenaline PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Hexoprenaline Permitted Daily Exposure (PDE) report (the Hexoprenaline PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Hexoprenaline Occupational Exposure Limit (OEL) report (the Hexoprenaline OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.